Stephen A. Sastra

This study engineers a probiotic bacteria to selectively target pancreatic cancer, improving survival and modulating the tumor microenvironment.

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

This study shows that combining gemcitabine with CXCR4 inhibitors and anti-PD1 therapy improves immune response and survival in pancreatic cancer models.